Sino Partners supports Chinese biomedical, health technology and clinical research organisations engaging with Oceania's healthcare R&D ecosystem, and helps Oceania research institutions and health businesses access Chinese R&D capability, manufacturing and investment.
China has emerged as a global leader in biomedical research, genomics, digital health technology and clinical trial capability. With significant government investment in life sciences and a manufacturing ecosystem capable of translating research into commercial product at scale, Chinese healthcare R&D is creating major opportunities for international collaboration.
Australia and New Zealand are internationally recognised for the quality of their clinical research, regulatory science and health innovation ecosystems. The combination of Chinese R&D investment and manufacturing capability with Oceania's clinical excellence and regulatory credibility creates powerful collaboration opportunities.
Specialist advisory at the frontier of China-Oceania healthcare research and commercial innovation.
Market entry strategy, TGA/Medsafe regulatory pathway advisory and commercial roll-out for Chinese biomedical technology, diagnostics and therapeutic device businesses entering Oceania.
Identification and facilitation of formal research partnerships between Chinese R&D institutions, biotech companies and Oceania universities, medical research institutes and clinical networks.
Advisory on Australia's Therapeutic Goods Administration (TGA) and New Zealand's Medsafe clinical trial frameworks, Ethics Committee processes, and trial site identification for Chinese clinical sponsors.
Commercial strategy and market entry advisory for Chinese health technology, diagnostics and pharmaceutical innovations seeking Oceania commercialisation.
Chinese investment in Oceania biotech, health technology and clinical research businesses - from early-stage to commercial stage.
Intellectual property strategy and regulatory affairs advisory for Chinese healthcare R&D businesses operating across the China-Oceania corridor.
Australia is consistently ranked among the world's top destinations for clinical trials - offering high-quality clinical networks, a robust regulatory framework, a well-educated patient population and internationally respected research institutions. New Zealand offers similar strengths with additional Pacific market access.
For Chinese healthcare R&D organisations seeking an English-language, Western regulatory pathway environment with high clinical quality, Oceania represents a strategically valuable destination for research investment and commercialisation.
Deep knowledge of TGA and Medsafe regulatory pathways for medical devices, diagnostics, therapeutics and digital health technologies.
Understanding of Australia and New Zealand's clinical research infrastructure, funding landscape and key institutional partners.
Established connections with Chinese biomedical technology developers, clinical research organisations and health innovation institutions.
Advisory on intellectual property protection strategies for innovations being developed or commercialised across the China-Oceania corridor.
Capability to structure and facilitate Chinese investment into Oceania healthcare R&D businesses at all stages of development.
From initial market assessment and regulatory strategy through to commercial launch and ongoing compliance management.
Contact our healthcare R&D advisory team to discuss collaboration opportunities, market entry strategy or investment objectives.
Start a Conversation →